A follow-up study for people with GSDIa who received DTX401
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study monitors the long-term health of people with Glycogen Storage Disease Type Ia who have already received the gene therapy DTX401, either in a previous clinical trial or after it was approved. The goal is to gather more information about their condition over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Glycogen Storage Disease Type Ia (GSDIa).
- You have already received the gene therapy DTX401, either as a full or partial dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine called BEAM-301 for people with a specific form of glycogen storage disease type Ia (GSDIa). The goal is to see if it can help reduce dangerous low blood sugar episodes.
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
This study follows participants who previously received the RGX-111 treatment to monitor their health over time. It helps researchers understand the long-term effects and safety of the therapy.
This study looks at the natural history (how the illness typically progresses) in people with GSD VI or GSD IX. It may help doctors better understand disease patterns, which can support future treatments.
This study follows people with rare types of glycogen storage disease (GSD) over time to learn more about how the disease progresses. It does not test a new treatment but will collect information to help future research.
This long-term follow-up study watches people who previously received the experimental gene therapy RGX-202 for Duchenne muscular dystrophy. It checks how patients are doing over time and does not involve any new treatment.
Hear when a new Glycogen Storage Disease Type Ia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.